Clinical Trial Detail

NCT ID NCT04306367
Title Study of Pembrolizumab and Olaparib in Bile Duct Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Georgetown University
Indications

intrahepatic cholangiocarcinoma

cholangiocarcinoma

gallbladder cancer

Therapies

Olaparib + Pembrolizumab

Age Groups: senior adult

No variant requirements are available.